About catridecacog
Recombinant coagulation factor XIII-A
Used for
- Prevents bleeding in people with congenital factor XIII A-subunit deficiency.
Usual adult dose
35 IU/kg injected under the skin every 28 days; adjust based on factor XIII activity and clinical response.
Usual dose in children
35 IU/kg injected under the skin every 28 days; adjust based on factor XIII activity and clinical response.
Common side effects
- Headache
- Pain in the arms or legs
- Injection-site reactions
- Increased liver enzymes
Important warnings
- For congenital factor XIII A-subunit deficiency, not other forms of factor XIII deficiency.
- Serious allergic reactions can occur.
- Antibodies may develop and reduce treatment effectiveness.
- Use and monitoring require specialist care.
Pregnancy
Limited human data; use only when clearly needed, weighing potential benefits and risks.
Breastfeeding
It is unknown whether catridecacog enters breast milk; weigh treatment benefits against potential risks.
Interactions
- No established clinically significant drug interactions are known.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.